Despite President Bush’s veto of the embryonic stem cell bill almost two months ago, many venture capitalists consider the stem cell market to be viable… though just not yet for some investors. When and why will a venture capitalist invest in a stem cell company? How does the venture industry view the stem cell controversy? Jennifer Jones of PodTech.net talks with Dr. Edgar Engleman, managing partner of Vivo Ventures, and probes their investment strategy and perspective today.
